Horrell Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Horrell Capital Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50	Closed	-$1K	–	237
2024 Q1	$1K	Hold	50	–	–	﹤0.01%	227
2023 Q4	$1K	Hold	50	–	–	﹤0.01%	219
2023 Q3	$1K	Hold	50	–	–	﹤0.01%	213
2023 Q2	$1K	Hold	50	–	–	﹤0.01%	211
2023 Q1	$1K	Hold	50	–	–	﹤0.01%	208
2022 Q4	$1K	Buy	+50	New	+$412	﹤0.01%	207
2018 Q1	–	Sell	-64	Closed	-$1K	–	183
2017 Q4	$1K	Hold	64	–	–	﹤0.01%	174
2017 Q3	$1K	Hold	64	–	–	﹤0.01%	172
2017 Q2	$1K	Hold	64	–	–	﹤0.01%	167
2017 Q1	$2K	Hold	64	–	–	﹤0.01%	166
2016 Q4	$2K	Hold	64	–	–	﹤0.01%	165
2016 Q3	$3K	Hold	64	–	–	﹤0.01%	159
2016 Q2	$3K	Buy	+64	New	+$3.49K	﹤0.01%	172

Other funds holding MACK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Horrell Capital Management's MACK Position: Q2 2024 in Review

Horrell Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 50 shares — an estimated $1K sold.

Horrell Capital Management first reported a position in MACK in Q2 2016 and held it in 13 quarters. The position peaked at $3K in Q3 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

Horrell Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
Horrell Capital Management sold 50 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1K.
Horrell Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2016 and held it in 13 quarters.
Horrell Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $3K in Q3 2016.
12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Horrell Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.